Results 111 to 120 of about 3,235 (226)

Which Is the Best Biologic for Nasal Polyps: An Updated Network Meta‐Analysis

Clinical and Translational Allergy
Background Direct comparative efficacy data for biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) remain limited, particularly for novel agents like tezepelumab, underscoring the need to identify optimal therapies for precision management ...
Xi Xu, Jinting Lin, Minting Luo, Qingwu Wu   +3 more
doaj   +1 more source

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma

Frontiers in Allergy
Thymic stromal lymphopoietin (TSLP) is an alarmin mainly released by airway epithelial cells injured by many environmental noxious agents such as aeroallergens, respiratory viruses, bacteria, airborne pollutants and cigarette smoking.
Corrado Pelaia, James Melhorn, Giovanni Paoletti, Giovanni Paoletti, Remo Poto, Remo Poto, Angelantonio Maglio, Claudia Crimi, Alessandro Vatrella, Giorgio Walter Canonica, Giorgio Walter Canonica, Girolamo Pelaia   +11 more
doaj   +1 more source

Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects

European Respiratory Journal
Extract We commend Wechsler et al. [1] for their insightful analysis on clinical response and remission with tezepelumab. Identifying predictors of response in asthma is essential for achieving remission [2, 3].
S. Mailhot-Larouche, John Busby, S. Couillard   +2 more
semanticscholar   +1 more source

COPD 2.0: Bronchodilators, biologics and beyond - A systematic review

Lung India
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and chronic inflammation. Conventional bronchodilators have been the mainstay of therapy; however, their efficacy in certain
Huda Shamim, Anil Kumar Singh, Rahul Sharma, Rajat Kumar Mishra   +3 more
doaj   +1 more source

Italian translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab

Respirology Case Reports
Severe asthma affects approximately 5%–10% of patients with asthma. Herein, we describe a case of non‐type 2 asthma that progressively worsened over the years. An 80‐year‐old woman was diagnosed with asthma 11 years back.
Yoshiro Kai, Kentaro Suzuki, Ryosuke Kataoka, Ichiro Sato, Shinji Tamaki, Shigeo Muro   +5 more
doaj   +1 more source

Successful switch to tezepelumab for severe asthma and chronic rhinosinusitis with nasal polyps

Asia Pacific Allergy
Chronic rhinosinusitis with nasal polyp (CRSwNP) is a type 2 inflammatory disease frequently associated with asthma. Patients with CRSwNP are typically treated with endoscopic sinus surgery and oral corticosteroids.
Y. Kai, Keiji Yoneyama
semanticscholar   +1 more source

Tezepelumab After Mepolizumab in Allergic Bronchopulmonary Mycosis: A Case Report

Cureus
We describe the case of a 43-year-old woman with allergic bronchopulmonary mycosis (ABPM) and severe asthma who improved clinically on mepolizumab with eosinophil suppression but had recurrent mucus plugs, persistent right-middle-lobe atelectasis, rising
N. Oda, Tomohiko Oka, Ryoko Tsuji, Tetsuya Takeguchi, Atsushi Shimonishi, Akihiko Taniguchi, Reo Mitani, Ichiro Takata   +7 more
semanticscholar   +1 more source

TSLP‐targeting therapy: Beyond allergy?

Clinical and Translational Medicine, 2023
Risa Ebina‐Shibuya, Warren J. Leonard
doaj   +1 more source

Chronic Rhinosinusitis With Nasal Polyps Successfully Treated With Tezepelumab After an Inadequate Response to Dupilumab: A Case Report

Cureus
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease that is often refractory to surgery and requires treatment with biologics, including dupilumab (DUP), a monoclonal antibody targeting IL-4/13.
Ryo Wakasugi, Takeshi Takahashi, Takanobu Sasaki, T. Koya, Arata Horii   +4 more
semanticscholar   +1 more source